
Antimicrobial Stewardship
Latest News

Latest Videos
Shorts





Podcasts
More News

Results from the global SNAP trial find penicillin as effective as, and safer than, cloxacillin or flucloxacillin for penicillin-susceptible Staphylococcus aureus bacteremia.

Results from the SNAP global trial find cefazolin as effective and safer than the antistaphylococcal penicillins cloxacillin or flucloxacillin for methicillin-sensitive S aureus bacteremia.

DOTS data on dalbavancin for complicated S aureus bacteremia and PETERPEN interim results for ESβL bloodstream infections provide potential options to revisit first-line therapy. Megan Klatt, PharmD, BCIDP, DPLA, discusses insights from these trials and how they can affect clinical practice and stewardship.

A look back at Q2 2026's most significant infectious disease developments, including landmark FDA approvals, a historic hantavirus outbreak, and an update on a mRNA influenza vaccine.

Lao-Tzu Allan-Blitz, MD, MPH, discusses treatment strategies including resistance-guided therapy with molecular gyrA assays and the goal of potentially reintroducing ciprofloxacin as therapy for this infection.

Preclinical findings demonstrate that the novel efflux pump inhibitor TXA14007 significantly enhances azithromycin activity against multidrug-resistant Gram-negative bacteria, supporting a potential new oral treatment strategy for difficult-to-treat infections. Jesus Rosado-Lugo, PhD, offers insights on the study at ASM Microbe 2026.

In May 2026, the FDA approved a combination product of cefepime and zidebactam for the treatment of complicated urinary tract infections, including pyelonephritis, providing a new treatment option for multidrug-resistant gram-negative organisms. Here is a clinical overview of the newly approved antibiotic.

The FDA has approved tebipenem pivoxil (Utebzi), the first oral carbapenem antibiotic in the US for adults with complicated urinary tract infections, including pyelonephritis, providing an effective oral alternative to IV therapy for many patients with resistant infections.

Meta-analysis finds approximately 1% of well-appearing outpatient infants aged 60 to 90 days with fever have an invasive bacterial infection.

The American Society for Microbiology (ASM) is leveraging its new phage therapy coordination efforts to connect researchers and clinicians, standardize approaches, and explore how bacteriophages could complement antibiotics in the fight against antimicrobial resistance. Colleen Kraft, MD, offers some insights on the organization's plans to help grow this medical modality.

A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.

American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, discusses how they are reorganizing its structure to create more focused scientific divisions while maintaining collaboration across disciplines and improving member engagement.

Effectiveness of post-exposure prophylaxis (PEP) with doxycycline for chlamydia and syphilis comes with increase in resistant gonorrhea.

Fluoroquinolones are broadly active and convenient, but black box warnings and resistance concerns have reshaped when and how clinicians should use them.

A 5-day course of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.

Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.

The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).

Eolas Medical has an AI-powered clinical platform looking to aid health care professionals in accessing localized antimicrobial guidelines instantly, improving prescribing accuracy, reducing errors, and strengthening patient safety. CEO Declan Kelly, MBBS, provides insights on the platform and how his company is trying to address gaps in antimicrobial stewardship.

Mortality rates from treatment-resistant gram-negative infections remain high despite increased use of newer antibiotics and corresponding susceptibility testing.

New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.

A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.

A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.

Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.
















































































































































































